Market Cap (In NOK)
66.83 Million
Revenue (In NOK)
354 Thousand
Net Income (In NOK)
-190.4 Million
Avg. Volume
238.75 Thousand
- Currency
- NOK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0774-8.998
- PE
- -0.49
- EPS
- -3.504
- Beta Value
- 1.639
- ISIN
- NO0010650013
- CUSIP
- R08326101
- CIK
- -
- Shares
- 38721372.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mr. Martin Olin
- Employee Count
- -
- Website
- https://www.bergenbio.com
- Ipo Date
- 2017-12-13
- Details
- BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
More Stocks
-
BWEFFBW Energy Limited
BWEFF
-
600117
-
ANSALAPI
-
MPGPYPageGroup plc
MPGPY
-
FFIE
-
CADECadence Bank
CADE
-
6361Ebara Corporation
6361
-
CXXIFC21 Investments Inc.
CXXIF